Quantcast

Latest Pneumococcal conjugate vaccine Stories

2009-05-07 14:23:00

WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that Professor Hanna Nohynek, M.D., Ph.D. has been appointed Head Consultant of Encorium's clinical vaccine research team. Dr. Nohynek has an impressive track record in...

2009-05-07 07:00:00

-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application (BLA) for Prevnar 13*, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein), which was submitted on March 31....

2009-05-05 08:39:40

Infants who receive the pneumococcal conjugate vaccine (PCV) following the combination vaccine for diphtheria, polio, tetanus, pertussis and Haemophilus influenzae type b (DPTaP-Hib vaccine) appear to experience less pain than those who are immunized in the opposite order, according to a report in the May issue of Archives of Pediatrics & Adolescent Medicine, a theme issue on vaccines. Injections are the most painful common medical procedure conducted in childhood, according to background...

2009-04-29 06:00:00

- 2009 First Quarter Reported Diluted Earnings per Share were $0.89, Consistent with the Prior Year, and Diluted Earnings per Share, Excluding Certain Significant Items, Increased 1% to $0.95 - Worldwide Net Revenue Decreased 6% for the 2009 First Quarter and Increased 2%, Excluding the Impact of Foreign Exchange - First Quarter Net Revenue Growth, Excluding the Impact of Foreign Exchange, was Driven by Increases of 23% for Enbrel (outside the U.S. and Canada), 19% for...

2009-03-31 08:30:00

- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease - COLLEGEVILLE, Pa., March 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Prevnar 13(TM), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein). Last year, the FDA granted Prevnar 13 Fast Track...

2009-03-05 02:05:00

SCHLIEREN, Switzerland, March 5 /PRNewswire/ -- - Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, today announced the successful closing of a CHF25 million (ca. US$22 million, EUR17 million) Series B financing. The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the...

5925904850fbb391d059adec16e388761
2009-01-26 13:35:00

Pfizer has entered into a deal worth $68 billion to buy rival drug maker Wyeth, the two companies announced. The U.S. drug maker Pfizer will now be able to protect itself from a revenue drop once its popular drug Lipitor and other products lose patent protection. The company will also be able to diversify its product portfolio due to Wyeth's presence in biotech drugs and vaccines. Pfizer is also expected to cut 10 percent of its global workforce, or 8,000 jobs, and shut some manufacturing...

2009-01-16 21:26:43

Researchers say a pediatric vaccine has been effective in reducing the rate of pneumococcal meningitis in the United States. The study, published in the New England Journal of Medicine, said the vaccine prevents several common types of meningitis and has helped reduce the rate of another strain of meningitis that affects children and adults. The University of Pittsburgh School of Medicine said a review of 1,379 cases of pneumococcal meningitis from 1998 through 2005 shows rates of the disease...

009e399214892f6ee06eb6e9096e69c91
2009-01-16 08:10:00

U.S. researchers said on Wednesday that a routine childhood vaccine used to prevent several common types of infections has helped cut the rate of a deadly form of meningitis by 30 percent in children and adults.Even those who haven't been vaccinated for meningitis may benefit from the Prevnar vaccine made by Wyeth. Studies show it significantly reduced cases of meningitis caused by pneumococcal bacteria strains covered by the vaccine.The researchers also noted a worrisome increase of...

2009-01-05 23:36:47

Commonly used pneumococcal polysaccharide vaccines do not appear to be effective in preventing pneumonia, Swiss and British researchers said. Dr. Matthias Egger of the University of Bern, Switzerland, and colleagues said that in many industrialized countries, pneumococcal vaccines are currently recommended to help prevent pneumonia in those age 65 and older, and for younger people with increased risk due to conditions like HIV. The study, a systematic review and meta-analysis, looked at 22...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related